News | February 19, 2022
Hetero’s molnupiravir Phase III studies show 65 % reduction in hospitalisation
Early viral clearance (negative RT-PCR) and significant clinical improvement were observed within five days of administering the antiviral drug. There were no fatalities reported during the study
